Review anchor
Alpha-2B adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Alpha-2B adrenergic receptor
CHEMBL1942
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-2B adrenergic receptor as ChEMBL target CHEMBL1942, mapped to UniProt P18089. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1942
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18089
Alpha-2B adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-2B adrenergic receptor matters
Alpha-2B adrenergic receptor is reviewed as Alpha-2B adrenergic receptor (UniProt P18089); the current evidence base includes 186 approved drugs, 2726 compounds, and 325 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Alpha-2B adrenergic receptor
Alpha-2B adrenergic receptor Sequence length is 450 aa.
Review this target as Alpha-2B adrenergic receptor, mapped to UniProt P18089. Sequence length is 450 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P18089
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 186 approved drugs, 2726 compounds, and 325 assays for this target. The dominant activity type is KI. CHEMBL1256414 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL1256414 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
186 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-2B adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P18089, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2726
Total Compounds
325
Total Assays
186
Approved Drugs
IC50: 918.0, KI: 1584.0, EC50: 110.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1256414
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL1255723
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL1256378
|
9.7 | Ki | — |
|
|
No preferred name
CHEMBL157138
|
9.6 | Ki | Clinical |
|
|
No preferred name
CHEMBL5517941
|
9.6 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LOFEXIDINE
CHEMBL17860
|
2018 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
DESLORATADINE
CHEMBL1172
|
2001 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
|
1999 |
|
|
KETOTIFEN
CHEMBL534
|
1999 |
|
|
KETOTIFEN FUMARATE
CHEMBL1633
|
1999 |
|
|
DEXMEDETOMIDINE
CHEMBL778
|
1999 |
|
|
RABEPRAZOLE
CHEMBL1219
|
1999 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
PRAMIPEXOLE
CHEMBL301265
|
1997 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
|
1996 |
|
|
MIRTAZAPINE
CHEMBL654
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
BRIMONIDINE
CHEMBL844
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
TICLOPIDINE
CHEMBL833
|
1991 |
|
|
DAPIPRAZOLE
CHEMBL1201216
|
1990 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
SELEGILINE
CHEMBL972
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
RILMENIDINE
CHEMBL289480
|
1987 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
FLUOXETINE
CHEMBL41
|
1987 |
|
|
GUANFACINE
CHEMBL862
|
1986 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
ASCORBIC ACID
CHEMBL196
|
1985 |
|
|
HALOPROGIN
CHEMBL1289
|
1982 |
|
|
GUANABENZ
CHEMBL420
|
1982 |
|
|
GENTIAN VIOLET
CHEMBL64894
|
1982 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
PRAZOSIN HYDROCHLORIDE
CHEMBL1558
|
1976 |
|
|
CLONIDINE
CHEMBL134
|
1974 |
|
|
CLONIDINE HYDROCHLORIDE
CHEMBL1705
|
1974 |
|
|
DROPERIDOL
CHEMBL1108
|
1970 |
Source Header